Page last updated: 2024-12-04

1-(3-chlorophenyl)biguanide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

**1-(3-Chlorophenyl)biguanide** is an organic compound that belongs to the class of biguanides.

**Structure and Properties:**

* **Chemical Formula:** C7H8ClN5
* **Molecular Weight:** 213.64 g/mol
* **Appearance:** White to off-white solid
* **Solubility:** Soluble in water, methanol, and ethanol

**Importance in Research:**

**1. Antidiabetic Activity:**
* 1-(3-Chlorophenyl)biguanide has been investigated for its potential antidiabetic properties.
* It is a potent inhibitor of hepatic glucose production, which is a key mechanism in the control of blood glucose levels.
* Studies have shown that it can lower blood glucose levels in animal models of diabetes.

**2. Antibacterial Activity:**
* Biguanides are known for their antibacterial activity, and 1-(3-Chlorophenyl)biguanide has exhibited antibacterial properties against a range of bacterial species.
* Its mechanism of action is believed to involve disruption of bacterial cell membranes.

**3. Anti-Inflammatory Activity:**
* Some research suggests that 1-(3-Chlorophenyl)biguanide may possess anti-inflammatory activity.
* It has been shown to inhibit the production of pro-inflammatory cytokines, which are involved in inflammation.

**4. Drug Development Potential:**
* The biological activities of 1-(3-Chlorophenyl)biguanide make it a potential candidate for drug development.
* Researchers are exploring its therapeutic potential in the treatment of diabetes, bacterial infections, and inflammatory conditions.

**5. Research Tool:**
* As a potent inhibitor of hepatic glucose production, 1-(3-Chlorophenyl)biguanide is a valuable research tool for studying glucose metabolism and diabetes.

**Note:**

* 1-(3-Chlorophenyl)biguanide is not a commercially available drug.
* Its therapeutic potential is still under investigation.
* Further research is needed to fully understand its mechanism of action and safety profile.

1-(3-chlorophenyl)biguanide: RN given refers to parent cp; a 5-HT3 receptor agonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID1354
CHEMBL ID13790
CHEBI ID32347
SCHEMBL ID2144213
SCHEMBL ID1229884
SCHEMBL ID8223193
SCHEMBL ID23306696
MeSH IDM0180668

Synonyms (64)

Synonym
bdbm50053615
BRD-K36965586-001-01-7
3-chlorophenyl-biguanide
meta-chlorphenylbiguanide
[3h]meta-chlorophenylbiguanide
gtpl2304
gtpl2287
BPBIO1_000112
NCGC00015188-01
tocris-0440
NCGC00024591-01
lopac-c-144
LOPAC0_000343
BIOMOL-NT_000138
48144-44-1
C13646
mcpbg
m-chlorophenylbiguanide
1-(3-chlorophenyl)biguanide
1 (3 chlorophenyl)biguanide
1-(m-chlorophenyl)biguanide hydrochloride
NCGC00024591-03
n-(3-chlorophenyl)imidodicarbonimidic diamide
imidodicarbonimidic diamide, n-(3-chlorophenyl)-
1-(m-chlorophenyl)biguanide
NCGC00024591-02
STK109167
NCGC00015188-05
AKOS002224857
m-chlorophenylbiguanidine
3-chloro-phenyl biguanide
chebi:32347 ,
CHEMBL13790 ,
AKOS003345860
2-(3-chlorophenyl)-1-(diaminomethylidene)guanidine
1-(3-chlorophenyl)-3-(diaminomethylidene)guanidine
STK663844
SCHEMBL2144213
1-carbamimidamido-n-(3-chlorophenyl)methanimidamide
CCG-204438
unii-910a4x901v
910a4x901v ,
m-chloro-phenyl-biguanide
bdbm82474
cas_2113-05-5
NCGC00015188-02
NCGC00015188-03
NCGC00015188-04
n-(3-chlorophenyl)-n'-(diaminomethylene)guanidine
n-(3-chlorophenyl)imidodicarbonimidic diamide hydrochloride
AB00691678-08
SCHEMBL1229884
SCHEMBL8223193
2-(3-chlorophenyl)-1-(diaminomethylene)guanidine
DTXSID70197436
NCGC00015188-06
Q5103143
1-(m-chlorphenyl)-biguanide
mfcd05854288
BRD-K36965586-003-03-9
SDCCGSBI-0050331.P002
NCGC00015188-09
SCHEMBL23306696
1-{[{[amino(imino)methyl]amino}(imino)methyl]amino}-3-chlorobenzene

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" In the presence of 100 microM 2-Me5-HT, the upper part of the 5-HT dose-response curve was shifted to the right but reached the same maximum value as in the absence of 2-Me5-HT."( The agonist properties of m-chlorophenylbiguanide and 2-methyl-5-hydroxytryptamine on 5-HT3 receptors in N1E-115 neuroblastoma cells.
Lummis, SC; Martin, IL; Sepúlveda, MI, 1991
)
0.28
"6 mg/kg), significantly shifted the methamphetamine dose-response curve to the left."( Effects of various serotonin agonists, antagonists, and uptake inhibitors on the discriminative stimulus effects of methamphetamine in rats.
Goldberg, SR; Kutkat, SW; Laufert, MD; Munzar, P; Nováková, J, 1999
)
0.3
" The dose-response curve was bell-shaped."( Interactions between the anxiogenic effects of CB1 gene disruption and 5-HT3 neurotransmission.
Aliczki, M; Halasz, J; Haller, J; Mikics, E; Vas, J, 2009
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
monochlorobenzenesAny member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
biguanidesA class of oral hypoglycemic drugs used for diabetes mellitus or prediabetes treatment. They have a structure based on the 2-carbamimidoylguanidine skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (40)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLS proteinHomo sapiens (human)Potency5.62340.35487.935539.8107AID624146
TDP1 proteinHomo sapiens (human)Potency16.50940.000811.382244.6684AID686978; AID686979
ThrombopoietinHomo sapiens (human)Potency3.16230.02517.304831.6228AID917; AID918
thyroid stimulating hormone receptorHomo sapiens (human)Potency0.12590.001318.074339.8107AID926
arylsulfatase AHomo sapiens (human)Potency8.49211.069113.955137.9330AID720538
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency32.46480.00207.533739.8107AID891
cytochrome P450 2C9 precursorHomo sapiens (human)Potency39.81070.00636.904339.8107AID883
D(1A) dopamine receptorHomo sapiens (human)Potency2.59280.02245.944922.3872AID488982
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency40.71410.031610.279239.8107AID884; AID885
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency1.00000.00106.000935.4813AID943
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency40.71411.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency40.71411.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency40.71411.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency40.71411.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency40.71411.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency40.71411.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency40.71411.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency40.71411.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency40.71411.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency40.71411.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency40.71411.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency39.81070.00638.235039.8107AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency40.71411.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency40.71411.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency40.71411.000012.224831.6228AID885
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency7.94331.000010.475628.1838AID1457
GABA theta subunitRattus norvegicus (Norway rat)Potency40.71411.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency40.71411.000012.224831.6228AID885
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency4.25620.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 3EHomo sapiens (human)Ki0.01740.00100.88359.9000AID6335; AID6338; AID6339; AID6343
5-hydroxytryptamine receptor 3BHomo sapiens (human)Ki0.01740.00100.87119.9000AID6335; AID6338; AID6339; AID6343
Integrin beta-3Homo sapiens (human)IC50 (µMol)190.60000.00010.632310.0000AID276738
Integrin alpha-V Homo sapiens (human)IC50 (µMol)190.60000.00010.625610.0000AID276738
D(1A) dopamine receptorHomo sapiens (human)Ki0.01700.00010.836310.0000AID6335
5-hydroxytryptamine receptor 3AHomo sapiens (human)Ki0.01740.00000.74119.9000AID6335; AID6338; AID6339; AID6343
5-hydroxytryptamine receptor 3DHomo sapiens (human)Ki0.01740.00100.88359.9000AID6335; AID6338; AID6339; AID6343
5-hydroxytryptamine receptor 3CHomo sapiens (human)Ki0.01740.00100.88359.9000AID6335; AID6338; AID6339; AID6343
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 3BHomo sapiens (human)EC50 (µMol)2.80000.00101.10032.8000AID1388000
5-hydroxytryptamine receptor 3AMus musculus (house mouse)EC50 (µMol)11.03700.80003.95249.6000AID431578; AID431580; AID431582; AID431585; AID431586; AID431587; AID431588; AID431589; AID431591; AID431593; AID431594; AID431595; AID431597; AID431598; AID431599; AID431600; AID431601; AID431602; AID431603; AID431604; AID431605; AID431606; AID431607; AID431608; AID431609; AID431610; AID431611
Delta-type opioid receptorMus musculus (house mouse)EC50 (µMol)34.40000.00110.40144.8000AID431599; AID431606
5-hydroxytryptamine receptor 3AHomo sapiens (human)EC50 (µMol)3.30000.00100.65503.8000AID1387999; AID1388000
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (143)

Processvia Protein(s)Taxonomy
serotonin receptor signaling pathway5-hydroxytryptamine receptor 3EHomo sapiens (human)
monoatomic ion transmembrane transport5-hydroxytryptamine receptor 3EHomo sapiens (human)
excitatory postsynaptic potential5-hydroxytryptamine receptor 3EHomo sapiens (human)
inorganic cation transmembrane transport5-hydroxytryptamine receptor 3EHomo sapiens (human)
regulation of membrane potential5-hydroxytryptamine receptor 3EHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 3EHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 3BHomo sapiens (human)
monoatomic ion transmembrane transport5-hydroxytryptamine receptor 3BHomo sapiens (human)
excitatory postsynaptic potential5-hydroxytryptamine receptor 3BHomo sapiens (human)
inorganic cation transmembrane transport5-hydroxytryptamine receptor 3BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 3BHomo sapiens (human)
regulation of membrane potential5-hydroxytryptamine receptor 3BHomo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin alpha-V Homo sapiens (human)
angiogenesisIntegrin alpha-V Homo sapiens (human)
vasculogenesisIntegrin alpha-V Homo sapiens (human)
cell adhesionIntegrin alpha-V Homo sapiens (human)
cell-matrix adhesionIntegrin alpha-V Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationIntegrin alpha-V Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-V Homo sapiens (human)
positive regulation of cell population proliferationIntegrin alpha-V Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin alpha-V Homo sapiens (human)
negative regulation of lipid storageIntegrin alpha-V Homo sapiens (human)
cell migrationIntegrin alpha-V Homo sapiens (human)
positive regulation of cell migrationIntegrin alpha-V Homo sapiens (human)
cell-substrate adhesionIntegrin alpha-V Homo sapiens (human)
negative regulation of lipid transportIntegrin alpha-V Homo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-V Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin alpha-V Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin alpha-V Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin alpha-V Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin alpha-V Homo sapiens (human)
endodermal cell differentiationIntegrin alpha-V Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin alpha-V Homo sapiens (human)
apoptotic cell clearanceIntegrin alpha-V Homo sapiens (human)
positive regulation of cell adhesionIntegrin alpha-V Homo sapiens (human)
symbiont entry into host cellIntegrin alpha-V Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin alpha-V Homo sapiens (human)
regulation of phagocytosisIntegrin alpha-V Homo sapiens (human)
negative chemotaxisIntegrin alpha-V Homo sapiens (human)
positive regulation of small GTPase mediated signal transductionIntegrin alpha-V Homo sapiens (human)
ERK1 and ERK2 cascadeIntegrin alpha-V Homo sapiens (human)
calcium ion transmembrane transportIntegrin alpha-V Homo sapiens (human)
transforming growth factor beta productionIntegrin alpha-V Homo sapiens (human)
entry into host cell by a symbiont-containing vacuoleIntegrin alpha-V Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandIntegrin alpha-V Homo sapiens (human)
positive regulation of intracellular signal transductionIntegrin alpha-V Homo sapiens (human)
negative regulation of entry of bacterium into host cellIntegrin alpha-V Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayIntegrin alpha-V Homo sapiens (human)
cell-cell adhesionIntegrin alpha-V Homo sapiens (human)
temperature homeostasisD(1A) dopamine receptorHomo sapiens (human)
conditioned taste aversionD(1A) dopamine receptorHomo sapiens (human)
behavioral fear responseD(1A) dopamine receptorHomo sapiens (human)
regulation of protein phosphorylationD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(1A) dopamine receptorHomo sapiens (human)
response to amphetamineD(1A) dopamine receptorHomo sapiens (human)
protein import into nucleusD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
activation of adenylate cyclase activityD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
synapse assemblyD(1A) dopamine receptorHomo sapiens (human)
memoryD(1A) dopamine receptorHomo sapiens (human)
mating behaviorD(1A) dopamine receptorHomo sapiens (human)
grooming behaviorD(1A) dopamine receptorHomo sapiens (human)
adult walking behaviorD(1A) dopamine receptorHomo sapiens (human)
visual learningD(1A) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(1A) dopamine receptorHomo sapiens (human)
astrocyte developmentD(1A) dopamine receptorHomo sapiens (human)
dopamine transportD(1A) dopamine receptorHomo sapiens (human)
transmission of nerve impulseD(1A) dopamine receptorHomo sapiens (human)
neuronal action potentialD(1A) dopamine receptorHomo sapiens (human)
dentate gyrus developmentD(1A) dopamine receptorHomo sapiens (human)
striatum developmentD(1A) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of cell migrationD(1A) dopamine receptorHomo sapiens (human)
peristalsisD(1A) dopamine receptorHomo sapiens (human)
operant conditioningD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
vasodilationD(1A) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
maternal behaviorD(1A) dopamine receptorHomo sapiens (human)
positive regulation of potassium ion transportD(1A) dopamine receptorHomo sapiens (human)
glucose importD(1A) dopamine receptorHomo sapiens (human)
habituationD(1A) dopamine receptorHomo sapiens (human)
sensitizationD(1A) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(1A) dopamine receptorHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(1A) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic potentiationD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic depressionD(1A) dopamine receptorHomo sapiens (human)
cellular response to catecholamine stimulusD(1A) dopamine receptorHomo sapiens (human)
modification of postsynaptic structureD(1A) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of neuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 3AHomo sapiens (human)
monoatomic ion transmembrane transport5-hydroxytryptamine receptor 3AHomo sapiens (human)
excitatory postsynaptic potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
inorganic cation transmembrane transport5-hydroxytryptamine receptor 3AHomo sapiens (human)
regulation of presynaptic membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 3AHomo sapiens (human)
regulation of membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 3DHomo sapiens (human)
monoatomic ion transmembrane transport5-hydroxytryptamine receptor 3DHomo sapiens (human)
excitatory postsynaptic potential5-hydroxytryptamine receptor 3DHomo sapiens (human)
inorganic cation transmembrane transport5-hydroxytryptamine receptor 3DHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 3DHomo sapiens (human)
regulation of membrane potential5-hydroxytryptamine receptor 3DHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 3CHomo sapiens (human)
monoatomic ion transmembrane transport5-hydroxytryptamine receptor 3CHomo sapiens (human)
excitatory postsynaptic potential5-hydroxytryptamine receptor 3CHomo sapiens (human)
inorganic cation transmembrane transport5-hydroxytryptamine receptor 3CHomo sapiens (human)
regulation of membrane potential5-hydroxytryptamine receptor 3CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 3CHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (36)

Processvia Protein(s)Taxonomy
serotonin-gated monoatomic cation channel activity5-hydroxytryptamine receptor 3EHomo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity5-hydroxytryptamine receptor 3EHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential5-hydroxytryptamine receptor 3EHomo sapiens (human)
serotonin-gated monoatomic cation channel activity5-hydroxytryptamine receptor 3BHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential5-hydroxytryptamine receptor 3BHomo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity5-hydroxytryptamine receptor 3BHomo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
opsonin bindingIntegrin alpha-V Homo sapiens (human)
protein kinase C bindingIntegrin alpha-V Homo sapiens (human)
fibroblast growth factor bindingIntegrin alpha-V Homo sapiens (human)
C-X3-C chemokine bindingIntegrin alpha-V Homo sapiens (human)
insulin-like growth factor I bindingIntegrin alpha-V Homo sapiens (human)
neuregulin bindingIntegrin alpha-V Homo sapiens (human)
virus receptor activityIntegrin alpha-V Homo sapiens (human)
fibronectin bindingIntegrin alpha-V Homo sapiens (human)
protease bindingIntegrin alpha-V Homo sapiens (human)
integrin bindingIntegrin alpha-V Homo sapiens (human)
voltage-gated calcium channel activityIntegrin alpha-V Homo sapiens (human)
protein bindingIntegrin alpha-V Homo sapiens (human)
coreceptor activityIntegrin alpha-V Homo sapiens (human)
metal ion bindingIntegrin alpha-V Homo sapiens (human)
transforming growth factor beta bindingIntegrin alpha-V Homo sapiens (human)
extracellular matrix bindingIntegrin alpha-V Homo sapiens (human)
extracellular matrix protein bindingIntegrin alpha-V Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via GsD(1A) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activityD(1A) dopamine receptorHomo sapiens (human)
protein bindingD(1A) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine bindingD(1A) dopamine receptorHomo sapiens (human)
arrestin family protein bindingD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(1A) dopamine receptorHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin-gated monoatomic cation channel activity5-hydroxytryptamine receptor 3AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 3AHomo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity5-hydroxytryptamine receptor 3AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 3DHomo sapiens (human)
serotonin-gated monoatomic cation channel activity5-hydroxytryptamine receptor 3DHomo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity5-hydroxytryptamine receptor 3DHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential5-hydroxytryptamine receptor 3DHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 3CHomo sapiens (human)
serotonin-gated monoatomic cation channel activity5-hydroxytryptamine receptor 3CHomo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity5-hydroxytryptamine receptor 3CHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential5-hydroxytryptamine receptor 3CHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (49)

Processvia Protein(s)Taxonomy
plasma membrane5-hydroxytryptamine receptor 3EHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 3EHomo sapiens (human)
serotonin-activated cation-selective channel complex5-hydroxytryptamine receptor 3EHomo sapiens (human)
neuron projection5-hydroxytryptamine receptor 3EHomo sapiens (human)
transmembrane transporter complex5-hydroxytryptamine receptor 3EHomo sapiens (human)
synapse5-hydroxytryptamine receptor 3EHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3EHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3BHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 3BHomo sapiens (human)
serotonin-activated cation-selective channel complex5-hydroxytryptamine receptor 3BHomo sapiens (human)
cell surface5-hydroxytryptamine receptor 3BHomo sapiens (human)
transmembrane transporter complex5-hydroxytryptamine receptor 3BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 3BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3BHomo sapiens (human)
neuron projection5-hydroxytryptamine receptor 3BHomo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
cytosolIntegrin alpha-V Homo sapiens (human)
plasma membraneIntegrin alpha-V Homo sapiens (human)
focal adhesionIntegrin alpha-V Homo sapiens (human)
cell surfaceIntegrin alpha-V Homo sapiens (human)
membraneIntegrin alpha-V Homo sapiens (human)
lamellipodium membraneIntegrin alpha-V Homo sapiens (human)
filopodium membraneIntegrin alpha-V Homo sapiens (human)
microvillus membraneIntegrin alpha-V Homo sapiens (human)
ruffle membraneIntegrin alpha-V Homo sapiens (human)
integrin alphav-beta1 complexIntegrin alpha-V Homo sapiens (human)
integrin alphav-beta3 complexIntegrin alpha-V Homo sapiens (human)
integrin alphav-beta5 complexIntegrin alpha-V Homo sapiens (human)
integrin alphav-beta6 complexIntegrin alpha-V Homo sapiens (human)
integrin alphav-beta8 complexIntegrin alpha-V Homo sapiens (human)
specific granule membraneIntegrin alpha-V Homo sapiens (human)
phagocytic vesicleIntegrin alpha-V Homo sapiens (human)
extracellular exosomeIntegrin alpha-V Homo sapiens (human)
integrin complexIntegrin alpha-V Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin alpha-V Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin alpha-V Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin alpha-V Homo sapiens (human)
external side of plasma membraneIntegrin alpha-V Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
nucleusD(1A) dopamine receptorHomo sapiens (human)
endoplasmic reticulum membraneD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
ciliumD(1A) dopamine receptorHomo sapiens (human)
presynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
dendritic spineD(1A) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
ciliary membraneD(1A) dopamine receptorHomo sapiens (human)
non-motile ciliumD(1A) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(1A) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3AHomo sapiens (human)
cleavage furrow5-hydroxytryptamine receptor 3AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin-activated cation-selective channel complex5-hydroxytryptamine receptor 3AHomo sapiens (human)
synapse5-hydroxytryptamine receptor 3AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3AHomo sapiens (human)
transmembrane transporter complex5-hydroxytryptamine receptor 3AHomo sapiens (human)
neuron projection5-hydroxytryptamine receptor 3AHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
plasma membrane5-hydroxytryptamine receptor 3DHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 3DHomo sapiens (human)
serotonin-activated cation-selective channel complex5-hydroxytryptamine receptor 3DHomo sapiens (human)
synapse5-hydroxytryptamine receptor 3DHomo sapiens (human)
transmembrane transporter complex5-hydroxytryptamine receptor 3DHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3DHomo sapiens (human)
neuron projection5-hydroxytryptamine receptor 3DHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3CHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 3CHomo sapiens (human)
serotonin-activated cation-selective channel complex5-hydroxytryptamine receptor 3CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 3CHomo sapiens (human)
transmembrane transporter complex5-hydroxytryptamine receptor 3CHomo sapiens (human)
neuron projection5-hydroxytryptamine receptor 3CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3CHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (69)

Assay IDTitleYearJournalArticle
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID431596Agonist activity at mouse 5HT3A F180A receptor mutant expressed in Xenopus oocyte by two-electrode voltage patch method2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
A comprehensive study on the 5-hydroxytryptamine(3A) receptor binding of agonists serotonin and m-chlorophenylbiguanidine.
AID431581Agonist activity at mouse 5HT3A Y143A receptor mutant expressed in Xenopus oocyte by two-electrode voltage patch method2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
A comprehensive study on the 5-hydroxytryptamine(3A) receptor binding of agonists serotonin and m-chlorophenylbiguanidine.
AID431589Agonist activity at mouse 5HT3A H185F receptor mutant expressed in Xenopus oocyte by two-electrode voltage patch method2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
A comprehensive study on the 5-hydroxytryptamine(3A) receptor binding of agonists serotonin and m-chlorophenylbiguanidine.
AID6339Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.2001Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12
The binding of arylguanidines at 5-HT(3) serotonin receptors: a structure-affinity investigation.
AID189727Compound tested for its 5-HT3 -Stimulant potency in rat relative to compound 6 ( Value = 1)1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Structure-activity relationships for the binding of arylpiperazines and arylbiguanides at 5-HT3 serotonin receptors.
AID431593Agonist activity at mouse 5HT3A W183F receptor mutant expressed in Xenopus oocyte by two-electrode voltage patch method2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
A comprehensive study on the 5-hydroxytryptamine(3A) receptor binding of agonists serotonin and m-chlorophenylbiguanidine.
AID431610Selectivity ratio of EC50 for mouse 5HT3A Y153A receptor mutant to EC50 for wild type mouse 5HT3A receptor2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
A comprehensive study on the 5-hydroxytryptamine(3A) receptor binding of agonists serotonin and m-chlorophenylbiguanidine.
AID431605Selectivity ratio of EC50 for mouse 5HT3A T186A receptor mutant to EC50 for wild type mouse 5HT3A receptor2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
A comprehensive study on the 5-hydroxytryptamine(3A) receptor binding of agonists serotonin and m-chlorophenylbiguanidine.
AID431594Agonist activity at mouse 5HT3A S182A receptor mutant expressed in Xenopus oocyte by two-electrode voltage patch method2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
A comprehensive study on the 5-hydroxytryptamine(3A) receptor binding of agonists serotonin and m-chlorophenylbiguanidine.
AID431609Selectivity ratio of EC50 for mouse 5HT3A Y143F receptor mutant to EC50 for wild type mouse 5HT3A receptor2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
A comprehensive study on the 5-hydroxytryptamine(3A) receptor binding of agonists serotonin and m-chlorophenylbiguanidine.
AID1426077Agonist activity at mouse TAAR1 expressed in HEK293 cells assessed as cAMP accumulation at 10 uM after 20 mins by BRET assay relative to beta-PEA2017European journal of medicinal chemistry, Feb-15, Volume: 127Novel biguanide-based derivatives scouted as TAAR1 agonists: Synthesis, biological evaluation, ADME prediction and molecular docking studies.
AID431608Selectivity ratio of EC50 for mouse 5HT3A I190V receptor mutant to EC50 for wild type mouse 5HT3A receptor2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
A comprehensive study on the 5-hydroxytryptamine(3A) receptor binding of agonists serotonin and m-chlorophenylbiguanidine.
AID431583Agonist activity at mouse 5HT3A I190A receptor mutant expressed in Xenopus oocyte by two-electrode voltage patch method2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
A comprehensive study on the 5-hydroxytryptamine(3A) receptor binding of agonists serotonin and m-chlorophenylbiguanidine.
AID1387999Agonist activity at human 5-HT43A receptor expressed in Xenopus laevis oocytes2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Progress in the discovery of small molecule modulators of the Cys-loop superfamily receptors.
AID431587Agonist activity at mouse 5HT3A T186A receptor mutant expressed in Xenopus oocyte by two-electrode voltage patch method2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
A comprehensive study on the 5-hydroxytryptamine(3A) receptor binding of agonists serotonin and m-chlorophenylbiguanidine.
AID431599Selectivity ratio of EC50 for mouse 5HT3A T181A receptor mutant to EC50 for wild type mouse 5HT3A receptor2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
A comprehensive study on the 5-hydroxytryptamine(3A) receptor binding of agonists serotonin and m-chlorophenylbiguanidine.
AID431588Agonist activity at mouse 5HT3A H185Y receptor mutant expressed in Xenopus oocyte by two-electrode voltage patch method2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
A comprehensive study on the 5-hydroxytryptamine(3A) receptor binding of agonists serotonin and m-chlorophenylbiguanidine.
AID6338Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-656302003Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6
Conformationally-restricted analogues and partition coefficients of the 5-HT3 serotonin receptor ligands meta-chlorophenylbiguanide (mCPBG) and meta-chlorophenylguanidine (mCPG).
AID1426081Agonist activity at mouse TAAR5 expressed in HEK293 cells assessed as cAMP accumulation after 20 mins by BRET assay2017European journal of medicinal chemistry, Feb-15, Volume: 127Novel biguanide-based derivatives scouted as TAAR1 agonists: Synthesis, biological evaluation, ADME prediction and molecular docking studies.
AID431601Selectivity ratio of EC50 for mouse 5HT3A W183F receptor mutant to EC50 for wild type mouse 5HT3A receptor2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
A comprehensive study on the 5-hydroxytryptamine(3A) receptor binding of agonists serotonin and m-chlorophenylbiguanidine.
AID431602Selectivity ratio of EC50 for mouse 5HT3A L184V receptor mutant to EC50 for wild type mouse 5HT3A receptor2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
A comprehensive study on the 5-hydroxytryptamine(3A) receptor binding of agonists serotonin and m-chlorophenylbiguanidine.
AID1388000Agonist activity at human 5-HT43AB receptor expressed in Xenopus laevis oocytes2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Progress in the discovery of small molecule modulators of the Cys-loop superfamily receptors.
AID6324Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist2002Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19
Electrostatic potential surfaces of 5-HT(3)R agonists suggest accessory cation-pi site adjacent to agonist binding domain.
AID431579Agonist activity at mouse 5HT3A T179A receptor mutant expressed in Xenopus oocyte by two-electrode voltage patch clamp method2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
A comprehensive study on the 5-hydroxytryptamine(3A) receptor binding of agonists serotonin and m-chlorophenylbiguanidine.
AID6335Binding affinity towards 5-hydroxytryptamine 3 receptor2002Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19
Electrostatic potential surfaces of 5-HT(3)R agonists suggest accessory cation-pi site adjacent to agonist binding domain.
AID431584Agonist activity at mouse 5HT3A D189A receptor mutant expressed in Xenopus oocyte by two-electrode voltage patch method2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
A comprehensive study on the 5-hydroxytryptamine(3A) receptor binding of agonists serotonin and m-chlorophenylbiguanidine.
AID1426079Agonist activity at human TAAR1 expressed in HEK293 cells assessed as cAMP accumulation at 10 uM after 20 mins by BRET assay relative to beta-PEA2017European journal of medicinal chemistry, Feb-15, Volume: 127Novel biguanide-based derivatives scouted as TAAR1 agonists: Synthesis, biological evaluation, ADME prediction and molecular docking studies.
AID431582Agonist activity at mouse 5HT3A I190V receptor mutant expressed in Xenopus oocyte by two-electrode voltage patch method2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
A comprehensive study on the 5-hydroxytryptamine(3A) receptor binding of agonists serotonin and m-chlorophenylbiguanidine.
AID431595Agonist activity at mouse 5HT3A T181A receptor mutant expressed in Xenopus oocyte by two-electrode voltage patch method2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
A comprehensive study on the 5-hydroxytryptamine(3A) receptor binding of agonists serotonin and m-chlorophenylbiguanidine.
AID431600Selectivity ratio of EC50 for mouse 5HT3A S182A receptor mutant to EC50 for wild type mouse 5HT3A receptor2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
A comprehensive study on the 5-hydroxytryptamine(3A) receptor binding of agonists serotonin and m-chlorophenylbiguanidine.
AID6329Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist2002Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19
Electrostatic potential surfaces of 5-HT(3)R agonists suggest accessory cation-pi site adjacent to agonist binding domain.
AID6343Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Structure-activity relationships for the binding of arylpiperazines and arylbiguanides at 5-HT3 serotonin receptors.
AID431585Agonist activity at mouse 5HT3A Q188A receptor mutant expressed in Xenopus oocyte by two-electrode voltage patch method2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
A comprehensive study on the 5-hydroxytryptamine(3A) receptor binding of agonists serotonin and m-chlorophenylbiguanidine.
AID431603Selectivity ratio of EC50 for mouse 5HT3A H185F receptor mutant to EC50 for wild type mouse 5HT3A receptor2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
A comprehensive study on the 5-hydroxytryptamine(3A) receptor binding of agonists serotonin and m-chlorophenylbiguanidine.
AID431591Agonist activity at mouse 5HT3A L184V receptor mutant expressed in Xenopus oocyte by two-electrode voltage patch method2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
A comprehensive study on the 5-hydroxytryptamine(3A) receptor binding of agonists serotonin and m-chlorophenylbiguanidine.
AID431606Selectivity ratio of EC50 for mouse 5HT3A I187A receptor mutant to EC50 for wild type mouse 5HT3A receptor2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
A comprehensive study on the 5-hydroxytryptamine(3A) receptor binding of agonists serotonin and m-chlorophenylbiguanidine.
AID431597Agonist activity at mouse 5HT3A Y153A receptor mutant expressed in Xenopus oocyte by two-electrode voltage patch method2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
A comprehensive study on the 5-hydroxytryptamine(3A) receptor binding of agonists serotonin and m-chlorophenylbiguanidine.
AID431604Selectivity ratio of EC50 for mouse 5HT3A H185Y receptor mutant to EC50 for wild type mouse 5HT3A receptor2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
A comprehensive study on the 5-hydroxytryptamine(3A) receptor binding of agonists serotonin and m-chlorophenylbiguanidine.
AID431586Agonist activity at mouse 5HT3A I187A receptor mutant expressed in Xenopus oocyte by two-electrode voltage patch method2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
A comprehensive study on the 5-hydroxytryptamine(3A) receptor binding of agonists serotonin and m-chlorophenylbiguanidine.
AID431592Agonist activity at mouse 5HT3A L184A receptor mutant expressed in Xenopus oocyte by two-electrode voltage patch method2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
A comprehensive study on the 5-hydroxytryptamine(3A) receptor binding of agonists serotonin and m-chlorophenylbiguanidine.
AID19834Partition coefficient in an aqueous 1-octanol buffer system by the shake-flask method2003Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6
Conformationally-restricted analogues and partition coefficients of the 5-HT3 serotonin receptor ligands meta-chlorophenylbiguanide (mCPBG) and meta-chlorophenylguanidine (mCPG).
AID431607Selectivity ratio of EC50 for mouse 5HT3A Q188A receptor mutant to EC50 for wild type mouse 5HT3A receptor2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
A comprehensive study on the 5-hydroxytryptamine(3A) receptor binding of agonists serotonin and m-chlorophenylbiguanidine.
AID167329Minimal effective dose for its 5-HT3 -Stimulant potency in rabbit bladder preparation.1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Structure-activity relationships for the binding of arylpiperazines and arylbiguanides at 5-HT3 serotonin receptors.
AID431611Selectivity ratio of EC50 for mouse 5HT3A Y153F receptor mutant to EC50 for wild type mouse 5HT3A receptor2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
A comprehensive study on the 5-hydroxytryptamine(3A) receptor binding of agonists serotonin and m-chlorophenylbiguanidine.
AID431578Agonist activity at wild type mouse 5HT3A receptor expressed in Xenopus oocyte by two-electrode voltage patch clamp method2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
A comprehensive study on the 5-hydroxytryptamine(3A) receptor binding of agonists serotonin and m-chlorophenylbiguanidine.
AID276738Inhibition of integrin alphavbeta3 mediated cell adhesion of human M21 cells to vitronectin2006Bioorganic & medicinal chemistry letters, Nov-15, Volume: 16, Issue:22
Discovery of small molecule inhibitors of integrin alphavbeta3 through structure-based virtual screening.
AID431598Agonist activity at mouse 5HT3A Y153F receptor mutant expressed in Xenopus oocyte by two-electrode voltage patch method2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
A comprehensive study on the 5-hydroxytryptamine(3A) receptor binding of agonists serotonin and m-chlorophenylbiguanidine.
AID431580Agonist activity at mouse 5HT3A Y143F receptor mutant expressed in Xenopus oocyte by two-electrode voltage patch method2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
A comprehensive study on the 5-hydroxytryptamine(3A) receptor binding of agonists serotonin and m-chlorophenylbiguanidine.
AID431590Agonist activity at mouse 5HT3A H185A receptor mutant expressed in Xenopus oocyte by two-electrode voltage patch method2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
A comprehensive study on the 5-hydroxytryptamine(3A) receptor binding of agonists serotonin and m-chlorophenylbiguanidine.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (146)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's54 (36.99)18.2507
2000's51 (34.93)29.6817
2010's35 (23.97)24.3611
2020's6 (4.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.38 (24.57)
Research Supply Index5.03 (2.92)
Research Growth Index4.41 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.66%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other151 (99.34%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]